PTK2B and glioblastoma: In GBM specifically, studies using both primary human GBM cells and the GL261/C57Bl/6 mouse GBM model have further demonstrated that Pyk2 inhibition not only reduces cell proliferation but also enhances the efficacy of temozolomide, the standard chemotherapeutic agent [25].